The KinematX Midcarpal Total Wrist Arthroplasty Registry
Launched by EXTREMITY MEDICAL · Jan 30, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The KinematX Midcarpal Total Wrist Arthroplasty Registry is a clinical trial aimed at understanding how well patients recover after having total wrist replacement surgery using the KinematX implant. The study will follow patients for up to 10 years to see how their wrist movement (like bending and gripping) improves over time, and to gather their personal experiences and satisfaction with the surgery. This information will help doctors learn more about the effectiveness of this treatment for various wrist conditions, such as arthritis and wrist injuries.
To participate in this study, patients must be between the ages of 18 and 85 and have certain wrist problems that require or have already undergone total wrist replacement surgery. Participants will have their wrist function and health tracked at different points after surgery, including 3, 6, and 12 months, and then yearly for up to 10 years. This study is currently recruiting and welcomes anyone eligible to join, whether they have already had the surgery or are planning to have it soon.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * one of the following diagnoses and planned (or previously completed) total wrist arthroplasty with the KinematX total wrist:
- • osteoarthritis or post-traumatic arthritis
- • scapholunate advanced collapse (SLAC/SNAC wrist),
- • inflammatory arthritis (rheumatoid, psoriatic, other),
- • crystalline advanced collapse (SCAC),
- • STT advanced collapse (STTAC),
- • ulnar translocation,
- • Kienbӧck disease,
- • radial malunion
- Exclusion Criteria:
- • \<18 years of age
- • \>85 years of age
- • Prisoners
- • Children
- • Pregnant women
- * Contraindications to receiving the KinematX:
- • Local, distant or systematic acute or chronic soft tissue or bony infection
- • Physiologically or psychologically compromised patient
- • Active wrist synovitis or severe carpal bone erosion
- • Suspected or documented metal allergy or intolerance
- • Insufficient extensor tendons
- • Inadequate skin, bone, neural or vascular status
- • Severe carpal bone malalignment, displacement, absorption, neoplastic, or carpal bone pathology
- • Sepsis
- • Osteomyelitis
- • Uncontrolled/untreated osteoporosis or metabolic bone disease
- • Metabolic or endocrinologic bone disorders
- • Osteomalacia
- • Distant foci of infections which may spread to the implant site
- • Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram
About Extremity Medical
Extremity Medical is a leading medical device company dedicated to advancing orthopedic and extremity surgery through innovative solutions. With a focus on enhancing patient outcomes and surgeon efficiency, the company develops state-of-the-art products for the treatment of complex musculoskeletal conditions. Extremity Medical’s commitment to research and development is reflected in its robust portfolio of clinical trials aimed at validating the safety and effectiveness of its cutting-edge technologies. By fostering collaboration with healthcare professionals and leveraging the latest advancements in medical science, Extremity Medical strives to improve the quality of care in the field of extremity surgery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Loma Linda, California, United States
Tampa, Florida, United States
Indianapolis, Indiana, United States
Indianapolis, Indiana, United States
Patients applied
Trial Officials
Brian Smekal
Study Director
Extremity Medical
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials